Gene
silencing fights mad cow disease
22:00
01 December 2006
NewScientist.com news service
Roxanne Khamsi
Silencing
the genes that produce prion proteins can dramatically slow the progression of
mad cow disease, suggests a new study in mice.
Researchers
say that the approach might one day work to treat human prion illnesses, such
as variant Creutzfeldt Jakob Disease (vCJD).
People
can contract vCJD after eating meat contaminated with mad cow disease. Though
the illness is extremely rare, it can lead to schizophrenia-like psychosis and
typically causes death within a year of diagnosis.
While
doctors can prescribe drugs to temporarily treat some of the symptoms of prion
disease, which include seizures, they still have no way to stop the progression
of the illness.
Alexander
Pfeifer at the University of Bonn in Germany, and colleagues, explored the possibility
of fighting prion disease in mice using a method of gene silencing known as RNA
interference (RNAi).
Embryo
virus
This method exploits messenger RNA (mRNA) sequences in the cell, which
are responsible producing proteins by using the animals genetic code as
an instruction list. RNAi relies on molecules that bind to mRNA sequences in the
cell, thereby preventing the production of specific proteins.
The
researchers used a harmless virus to carry RNAi code into the mouse cells, which
specifically disrupts the mRNA sequences that produce normal prion proteins.
When
simply injected into the bloodstream these viral agents do not easily reach brain
cells those most affected by prion disease. So researchers exposed mouse
embryos to the virus. Because the embryonic cells took up the virus at an early
stage, many of the brain cells they generated contained the RNAi code..
Longer
life
Pfeifer and his collaborators, including Hans Kretzchmar at the University
of Munich, Germany, then injected the brains of the mice with infectious scrapie
prions from sheep. The mice with the highest proportion of brain cells containing
RNAi code roughly 85% lived about 230 days after infection. Normal
mice, by comparison, typically died within 170 days.
Researchers
say the RNAi worked because it reduced the production of normal prions, which
are thought to become miss-folded and dangerous after coming into contact with
infectious prions.
Pfeifer
notes that delivering RNAi to patients remains a challenge. He says that researchers
are now conducting animal tests to see if the engineered viruses that prevent
prion production can be delivered straight to the brain through a catheter.
Vaccine
approach
Other approaches currently being developed to fight prion disease,
such as a vaccine, would be much easier to administer if they prove successful,
according to Qingzhong Kong of Case Western Reserve University in Cleveland, Ohio,
US (see Two vaccines show promise against prion disease).
Kong
says there is a danger that the harmless virus used in an RNAi could mix with
a patient infected with another retrovirus, such as HIV. In a worst-case scenario,
this kind of recombination could potentially give rise to a more aggressive form
of HIV, he warns, which could in theory then be passed on.
Experts
also say that stopping prion production could have unintended side effects. Recent
studies have suggested that these proteins help new nerve cells form (see When
prions are 'good for the brain'). But Kong says that even if anti-prion RNAi does
slow nerve formation to some degree, this side effect is preferable to the fatal
consequences of vCJD.
Journal:
Journal of Clinical Investigation (DOI: 10.1172/JCI29236)